Synaptogenix Inc (SNPX)

[SF Wolf]

blu, I believe most of your concerns, at this stage of the Byrostatin trials, will be addressed in the Ph2b open label and Phase3 study designs.

The question to ask yourself is why did the FDA allow Neurotrope to alter the Ph2b study in mid-course and to shorten its duration?

I would argue that that action is very unusual for the FDA.

Neurotrope would have had to file a petition with convincing back-up data for the FDA to agree to the changes.

That, in my mind, is the most compelling argument to date that NTRP will report a positive outcome in the Ph2b trial.